Idorsia Net Income From Continuing Ops Over Time
| IDIA Stock | CHF 3.91 0.06 1.51% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Idorsia Performance and Idorsia Correlation. Idorsia |
Cross Equities Net Income From Continuing Ops Analysis
Compare Idorsia and related stocks such as Basilea Pharmaceutica, PolyPeptide Group, and Kuros Biosciences Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BSLN | (41.5 M) | (41.5 M) | (41.5 M) | (41.5 M) | (41.5 M) | (61.6 M) | (51.3 M) | (19.4 M) | (31.4 M) | (22.4 M) | (14.7 M) | (6.8 M) | 12.1 M | 10.5 M | 77.6 M | 89.2 M | 93.7 M |
| PPGN | 23.8 M | 23.8 M | 23.8 M | 23.8 M | 23.8 M | 23.8 M | 23.8 M | 23.8 M | 23.8 M | 25.7 M | 31.3 M | 47.3 M | 7.8 M | (51.4 M) | (19.6 M) | (17.6 M) | (16.7 M) |
| KURN | (5.8 M) | (5.8 M) | (5.8 M) | (5.8 M) | (5.8 M) | (5.8 M) | (19.7 M) | (16.5 M) | (11.7 M) | (11.3 M) | (11.5 M) | (7.5 M) | (14.6 M) | (13.7 M) | (3.7 M) | (4.3 M) | (4.5 M) |
| MOLN | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (149 K) | (18.6 M) | (25.4 M) | (37 M) | (36.3 M) | (62.8 M) | (63.8 M) | 117.9 M | (59.6 M) | (54 M) | (48.6 M) | (46.2 M) |
| SANN | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | 5.9 M | (35.4 M) | (51.5 M) | (54.2 M) | (19 M) | (67.7 M) | (55.5 M) | (71.1 M) | 54.8 M | (42 M) | (37.8 M) | (39.7 M) |
| MED | 7.3 M | 7.3 M | 7.3 M | 7.3 M | 7.3 M | 7.3 M | 3.3 M | 866.5 K | 4.2 M | 2.1 M | (943.6 K) | 6.8 M | (5.8 M) | 620 K | 3.5 M | 3.2 M | 1.8 M |
| NWRN | (10.1 M) | (10.1 M) | (10.1 M) | (10.1 M) | (10.1 M) | (22.8 M) | (15.2 M) | (5.3 M) | (15 M) | (20.2 M) | (21 M) | (14.9 M) | (17.5 M) | (16.2 M) | 15.8 M | 18.2 M | 19.1 M |
| ADXN | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (4.2 M) | (3.1 M) | (3.3 M) | (1.6 M) | (14.8 M) | (12.9 M) | (15.4 M) | (20.8 M) | (10.6 M) | (4.9 M) | (4.4 M) | (4.6 M) |
| COPN | 73.3 M | 73.3 M | 73.3 M | 73.3 M | 73.3 M | 248.2 M | 19.3 M | (32.4 M) | (18.1 M) | (24.5 M) | (7.9 M) | 21.7 M | 17.5 M | (4.7 M) | 133.2 M | 119.9 M | 125.9 M |
Idorsia and related stocks such as Basilea Pharmaceutica, PolyPeptide Group, and Kuros Biosciences Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Idorsia | IDIA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | Hegenheimermattweg 91, Allschwil, |
| Exchange | SIX Swiss Exchange |
CHF 3.91
Additional Tools for Idorsia Stock Analysis
When running Idorsia's price analysis, check to measure Idorsia's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Idorsia is operating at the current time. Most of Idorsia's value examination focuses on studying past and present price action to predict the probability of Idorsia's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Idorsia's price. Additionally, you may evaluate how the addition of Idorsia to your portfolios can decrease your overall portfolio volatility.